title: Novel agents in the treatment of multiple myeloma: a review about the future.
abstract: Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.
authors.affiliation: Department of Medicine, New York University, New York, USA.
authors.forename: Leonard
authors.initials: L
authors.lastname: Naymagon
authors.affiliation: Department of Medicine, New York University, New York, USA. Maher.Abdulhay@nyumc.org.|Perlmutter Cancer Center, New York University, New York, USA. Maher.Abdulhay@nyumc.org.|NYU School of Medicine, 240 East 38th Street, 19 Floor, New York, NY, 10016, USA. Maher.Abdulhay@nyumc.org.
authors.forename: Maher
authors.identifier: 0000-0003-1041-7689
authors.initials: M
authors.lastname: Abdul-Hay
mesh_terms: D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D009101:Multiple Myeloma / Q000188:drug therapy*
keywords: AKT inhibitors; Alkylating agents; BTK inhibitors; CDK inhibitors; HDACIs; IL-6 inhibitors; Immunomodulators; Kinesin spindle protein inhibitors; Monoclonal antibodies; Multiple myeloma; Novel agents; PI3K inhibitors; Proteasome inhibitors